July 24, 2006
Deep
Brain Stimulation — fMRI Showing Researchers Why Neurological
Procedure Helps Patients With Parkinson’s
By Dan Harvey
For The Record
Vol. 18 No. 15 P. 34
Deep brain stimulation (DBS), a neurological procedure
that involves surgical implantation of electrodes, is an effective and
widely used treatment for patients with Parkinson’s disease. The
implanted electrodes deliver electrical impulses to brain regions that
control the condition’s characteristic tremors and other symptoms.
For patients with Parkinson’s, DBS of the subthalamic
nucleus in the brain has become a standard of care. However, physicians
aren’t sure exactly why the accepted procedure works so well.
“Although DBS has been used for a while, the exact
mechanisms of action aren’t quite clear to us,” says Michael
D. Phillips, MD, a neuroradiologist with The Cleveland Clinic’s
Center for Neurological Restoration.
But they’re trying to find out. Phillips and colleagues
are engaged in ongoing research hoping to identify the mechanisms underlying
the therapeutic effects. Specifically, The Cleveland Clinic researchers
are employing functional magnetic resonance imaging (fMRI) to answer
some of their questions. Thus far, relatively few MRI examinations have
been performed to evaluate the function of DBS.
Their initial research shed some light on these action
mechanisms, showing the parts of the brain that respond to DBS and indicate
apparently significant cerebral activation patterns. In addition, their
work has shown that with controlled conditions, fMRI can be performed
safely during DBS. This is an important finding. While fMRI is often
used to view brain activity, it can be hazardous when used to monitor
DBS. Risks involve damage to the DBS pulse generator and induced currents
and heating within DBS leads, which can cause patient injury.
When it comes to the mechanisms of action, the researchers
say their work is introductory. Even so, their research represents a
step forward, as it will open doors to other studies. Future studies
could provide valuable information about the pathophysiology of the
disease and optimization of patient response to DBS. Moreover, it could
point toward future advances in neurostimulation technologies and approaches.
Stimulating the Brain
DBS involves surgical implantation of a neurostimulator, a device that
electronically stimulates targeted regions of the brain. For patients
with Parkinson’s, this stimulation blocks the abnormal nerve signals
that cause the most common and visible symptoms associated with their
affliction, such as tremors and rigidity.
Before the procedure, a neurosurgeon employs imaging
technology, such as MRI or computed tomography, to pinpoint the regions
in the brain where these abnormal nerve signals arise. Usually, these
areas include the thalamus, subthalamic nucleus, and globus pallidus.
The neurosurgeon then places the DBS system in the appropriate region.
A DBS system includes a lead wire, an extension wire,
and the neurostimulator. The lead wire, or electrode, is inserted through
an opening in the skull, with its tip positioned in the targeted brain
area. The extension wire is inserted under the skin of the head, neck,
or shoulder and connects the lead wire to the neurostimulator, which
is usually placed under skin, either near the collarbone or abdomen
or in the lower chest region.
When the system is in place, the neurostimulator generates
electrical impulses that flow through the extension wire and the lead
and then into the brain, where they block the abnormal nerve signals.
DBS of the thalamus and subthalamic nucleus has demonstrated
therapeutic value in the management of Parkinson’s symptoms, and
it provides several significant advantages: The system won’t damage
healthy brain tissue; the provided neurostimulation can be readjusted
to accommodate a patient’s changing condition; and the DBS system
can be easily removed if a better procedure is developed.
Unanswered Questions
In developing their study, The Cleveland Clinic researchers wanted to
determine the pattern of fMRI activation at 3 Tesla (3T) produced by
DBS of the subthalamic nucleus for treatment of Parkinson’s disease,
as few patients with Parkinson’s have been examined in such a
fashion.
“We’re trying to better understand how DBS
works,” says Phillips. “We thought that if we could perform
fMRI while a patient was being stimulated, we could learn which portions
of the brain were being directly affected by DBS.”
The researchers employed fMRI because they thought it
would best address the questions relating to the mechanisms of action.
A noninvasive fMRI can map brain activity through a specialized sequence
that detects small changes in local cerebral blood flow resulting from
neuronal activity. Compared with radioisotopic imaging studies, such
as positron emission tomography or single-photon emission computed tomography,
which are often employed for similar purposes, fMRI offers several advantages:
It avoids usage of intravenous contrast material, provides improved
spatial resolution, and has better temporal resolution. Further, the
researchers performed fMRI at 3T, which offers higher resolution of
the deep brain structures compared with 1.5T MR systems.
The research team includes Phillips; Kenneth B. Baker,
PhD; Mark J. Lowe, PhD; Jean A. Tkach, PhD; Scott E. Cooper, MD, PhD;
Brian H. Kopell, MD; and Ali R. Rezai, MD. They reported their findings
in the April issue of Radiology and a paper titled “Parkinson
Disease: Pattern of Functional MR Imaging Activation during Deep Brain
Stimulation of Subthalamic Nucleus—Initial Experience.”
Going into their study, they theorized that they’d
see a consistent pattern of cerebral activation in patients with Parkinson’s
who had DBS leads placed in their subthalamic nucleus. They also anticipated
that, thanks to extensive pretesting, fMRI used with DBS would be safe
for patients. Their findings indicate that they were correct on both
counts.
Patterns Revealed
The study involved five subjects, male and female, ranging in age from
31 to 74, who had undergone placement of bilateral DBS electrodes in
the subthalamic nucleus (one in each brain hemisphere).
Following extensive phantom safety testing of DBS lead
systems, the subjects were examined by using fMRI one or two days after
the surgical stimulator placement. First, the subjects underwent imaging
performed without the DBS leads attached to an external pulse generator
placed in an MR imaging control room. Imaging was performed with a 3-D
data set for anatomic localization.
After completion of the anatomic imaging data set, a
single DBS lead was attached to the pulse generator and fMRI acquisitions
were performed by using prospectively motion-corrected, 2-D, gradient-echo,
echo-planar imaging. In all, nine electrodes were stimulated.
Subjects underwent a neurologic examination immediately
before and after imaging. The results of all examinations for all subjects
indicated no neurological changes.
Activation was seen in eight of nine electrodes stimulated.
Further, this activation revealed a clearly discernable, consistent
pattern. As a result of their findings, the researchers concluded that
effective DBS of the subthalamic nucleus produces a consistent pattern
of ipsilateral activation, primarily in the globus pallidus externa
and thalamus, in response to the electrode stimulation.
Safety Factor
The researchers also wanted to determine the safety of DBS electrode
stimulation during an fMRI procedure, as few fMRI studies have been
performed in patients with implanted DBS systems. Evaluation of DBS
performed with MRI is potentially dangerous. Possible hazards include
movement of DBS leads caused by the magnetic field of the MRI machine,
damage to the DBS implanted pulse generator, induced currents within
the lead system, and heating within DBS leads. “Heating inside
the lead system can potentially hurt someone,” says Phillips.
For instance, the rapid heating associated with MRI—typically
occurring within the first 90 seconds of imaging—without adequate
time for dispersion could cause a focal brain lesion.
However, the researchers indicated that the results
of their study demonstrated that, with carefully controlled specific
conditions, fMRI can be performed safely at 3T during DBS. Their combined
results for the heating and safety experiments demonstrated that none
of the imaging sequences produced a temperature increase greater than
1.4° C. Therefore, with the specific configuration they used—which
included specific pulse sequences, wiring of the electrodes and lead
extenders, and imaging platform—fMRI with DBS was deemed safe
for imaging in humans.
As those findings suggest, safety entails a great deal
of effort, as safety data is specific to pulse sequences and can’t
be generalized among imaging platforms. That is, safety testing of each
MRI system and operating software must be conducted before any imaging
can be performed.
“Safety testing doesn’t work consistently
from one magnet to the next,” emphasizes Phillips. “We did
a great deal of safety testing before we even did our first subject,
and anyone who would want to do this kind of work would have to do extensive
testing beforehand on their own equipment. So, it is not something that
you can just go out and do. It really involves a tremendous amount of
preliminary work.”
Further Research
While the study findings indicate that fMRI during DBS of the subthalamic
nucleus can be performed safely at 3T with carefully specified conditions,
and that therapeutically effective DBS of the subthalamic nucleus produces
a consistent pattern of activation in deep brain motor structures, Phillips
points out that the work is essentially preliminary. “We still
have a lot more to learn,” he points out.
And a lot more work to do, he adds: “We’re
funded by the National Institutes of Health to perform studies on 60
or more patients so that we can better understand exactly what’s
going on. Basically, with this study, we’ve only just began.”
Still, he points out that the study suggests they’re
on the right track. “The study showed us that we could do this,
and it revealed pretty consistent activation in the group of five patients.”
He admits that while the number is not enough to make
a strong statement, the research suggests which brain regions are most
likely involved in the efficacy of DBS, and that’s an important
finding.
As for the future research, Phillips expects it will
help researchers determine which patients receive optimal stimulation.
“But that will require a lot of work,” he says. “We’re
looking forward to fixing our protocols, which could give us a better
idea of what is going on in the cortex, which is hard for us to do right
now. So, we’ve essentially completed the first of a whole series
of steps.”
— Dan Harvey is a freelance writer based in
Wilmington, Del.
Subscribe to For
the Record Magazine!
|